Asked by: Manuela Perteghella (Liberal Democrat - Stratford-on-Avon)
Question to the Department for Work and Pensions:
To ask the Secretary of State for Work and Pensions, what assessment he has made of the potential impact of repeated disability benefit assessments on the mental and physical wellbeing of claimants, including people with autism spectrum disorder and other neurodevelopmental conditions; and whether her Department has assessed the potential merits of considering evidence of a long-term health condition or disability submitted through an assessment for a different welfare benefit, including across applications for Personal Independence Payment and Universal Credit.
Answered by Stephen Timms - Minister of State (Ministry of Housing Communities and Local Government) (Equalities)
The Timms Review is considering the role of PIP in enabling disabled people and those with long-term health conditions to live independently and participate fully in society, and how it can remain fair and fit for the future. Listening to the lived experience and expertise of disabled people, including concerns about repeat assessments, is critical to the Review’s success. The Review will report its recommendations to the Secretary of State in the Autumn.
Asked by: Manuela Perteghella (Liberal Democrat - Stratford-on-Avon)
Question to the Ministry of Housing, Communities and Local Government:
To ask the Secretary of State for Housing, Communities and Local Government, what assessment he has made of the potential impact of ongoing service charges and maintenance fees in age-restricted retirement housing developments after a property becomes vacant on residents and their families; and if he will review protections for leaseholders who incur annual charges while attempting to sell retirement flats.
Answered by Matthew Pennycook - Minister of State (Housing, Communities and Local Government)
I refer the hon. Member to the answer given to Question UIN 4726 on 8 June 2026.
Asked by: Manuela Perteghella (Liberal Democrat - Stratford-on-Avon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to facilitate access on the NHS to baricitinib for children and young people with juvenile idiopathic arthritis (JIA); and whether he has considered alternative commissioning or funding routes for that treatment in the absence of a NICE appraisal.
Answered by Preet Kaur Gill
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based recommendations for the National Health Service on whether new, licensed medicines represent a clinically and cost-effective use of NHS resources. The NHS in England is legally required to fund medicines recommended by NICE.
NICE has unfortunately been unable to develop guidance for the NHS on the use of baricitinib for treating juvenile idiopathic arthritis in people two years old and over because the company, Eli Lilly, did not provide an evidence submission. NICE will review its decision if the company decides to make a new evidence submission.
Decisions on whether to fund medicines in the absence of NICE guidance are for NHS commissioners. NHS England does not fund medicines where the company has not engaged with NICE. This is to avoid a potential pathway for circumventing the NICE appraisal process. NHS England’s policy on non-submission of data to NICE is available at the following link: